Glistenings and PCO Evaluation for the Envista MX60

Evaluation of Glistenings and Posterior Capsule Opacification Following Envista MX60 Intraocular Lens Implantation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02698943

Enrollment

Registered

2016-03-04

Start date

2015-09-30

Completion date

2016-02-29

Last updated

2016-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cataract

Keywords

cataract; intraocular lens; posterior capsule opacification; glistening; ENVISTA

Brief summary

Posterior capsule opacification (PCO) and glistenings development is among the primary reasons for sub-optimal visual capacity following cataract extraction surgery. Primary objective of this study is to evaluate the incidence of PCO and glistenings of the popular envista MX-60 intraocular lens (Bausch + Lomb) in a random sample of cataract patients who underwent phacoemulsification at least 1 year prior to their enrollment at the study

Interventions

PROCEDUREPhacoemulsification

Phacoemulsification for cataract extraction with Envista MX-60 implantation

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

60 Years to 80 Years

Healthy volunteers

Inclusion criteria

Diagnosis of senile cataract with stage 3 nuclear opalescence according to the Lens Opacities Classification System III (LOCS-3) grading scale

Exclusion criteria

Endothelial cell count less than 1900, glaucoma, IOP-lowering medications, former incisional surgery, former diagnosis of corneal disease, diabetes or autoimmune diseases

Design outcomes

Primary

Measure	Time frame	Description
Glistenings	1 year	Evaluation of glistenings using Scheimpflug analysis
Posterior capsule Opacification (PCO)	1 year	Evaluation of PCO using EPCO software

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026